Болезнь Паркинсона (БП) - сложное нейродегенеративное заболевание, характеризующееся сочетанием двигательных и недвигательных симптомов, не имеющих четко определенных диагностических клинических маркеров. Первичные двигательные признаки, такие как брадикинезия, тремор покоя, ригидность и потеря постуральных рефлексов, являются основными признаками, используемыми в современной клинической практике для идентификации пациентов с БП.
Болезнь Паркинсона (БП) - сложное нейродегенеративное заболевание, характеризующееся сочетанием двигательных и недвигательных симптомов, не имеющих четко определенных диагностических клинических маркеров. Первичные двигательные признаки, такие как брадикинезия, тремор покоя, ригидность и потеря постуральных рефлексов, являются основными признаками, используемыми в современной клинической практике для идентификации пациентов с БП.
| № | Muallifning F.I.Sh. | Lavozimi | Tashkilot nomi |
|---|---|---|---|
| 1 | Asqarov E.S. | г Ташкент | Alfraganus university |
| № | Havola nomi |
|---|---|
| 1 | Parkinson, J. An essay on the Shaking Palsy. Arch. Neurol. 1969, 20, 441–445. Kalia, L.V.; Lang, A.E. Parkinson’s disease. Lancet 2015, 386, 896–912. Mhyre, T.R.; Boyd, J.T.; Hamill, R.W.; Maguire-Zeiss, K.A. Parkinson’s disease. Subcell Biochem. 2012, 65, 389–455. Hirsch, L.; Jette, N.; Frolkis, A.; Steeves, T.; Pringsheim, T. The Incidence of Parkinson’s Disease: A Systematic Review and Meta-Analysis. Neuroepidemiology 2016, 46, 292–300. Driver, J.A.; Logroscino, G.; Gaziano, J.M.; Kurth, T. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 2009, 72, 432–438. Lee, Y.H.; Cha, J.; Chung, S.J.; Yoo, H.S.; Sohn, Y.H.; Ye, B.S.; Lee, P.H. Beneficial effect of estrogen on nigrostriatal dopaminergic neurons in drug-naïve postmenopausal Parkinson’s disease. Sci. Rep. 2019, 9, 10531. Wirdefeldt, K.; Gatz, M.; Pawitan, Y.; Pedersen, N.L. Risk and protective factors for Parkinson’s disease: A study in Swedish twins. Ann. Neurol. 2005, 57, 27–33 Prediger, R.D. Effects of caffeine in Parkinson’s disease: From neuroprotection to the management of motor and non-motor symptoms. J. Alzheimer’s Dis. JAD 2010, 20, S205–S220. Huse, D.M.; Schulman, K.; Orsini, L.; Castelli-Haley, J.; Kennedy, S.; Lenhart, G. Burden of illness in Parkinson’s disease. Mov. Disord.: Off. J. Mov. Disord. Soc. 2005, 20, 1449–1454. Findley, L.J. The economic impact of Parkinson’s disease. Parkinsonism Relat. Disord. 2007, 13, S8–S12 Jankovic, J. Parkinson’s disease: Clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 2008, 79, 368–376 Rizek, P.; Kumar, N.; Jog, M.S. An update on the diagnosis and treatment of Parkinson disease. CMAJ: Can. Med. Assoc. J. J. l’Assoc. Med. Can. 2016, 188, 1157–1165. D’Costa, D.F.; Sheehan, L.J.; Phillips, P.A.; Moore-Smith, B. The levodopa test in Parkinson’s disease. Age Ageing 1995, 24, 210–212. Massano, J.; Bhatia, K.P. Clinical approach to Parkinson’s disease: Features, diagnosis, and principles of management. Cold Spring Harb. Perspect. Med. 2012, 2, a008870. Meara, J.; Bhowmick, B.K.; Hobson, P. Accuracy of diagnosis in patients with presumed Parkinson’s disease. Age Ageing 1999, 28, 99–102 Nandipati, S.; Litvan, I. Environmental Exposures and Parkinson’s Disease. Int. J. Environ. Res. Public Health 2016, 13, 881. Lock, E.A.; Zhang, J.; Checkoway, H. Solvents and Parkinson disease: A systematic review of toxicological and epidemiological evidence. Toxicol. Appl. Pharmacol. 2013, 266, 345–355. Lai, C.-Y.; Chou, M.-C.; Lin, C.-L.; Kao, C.-H. Increased risk of Parkinson disease in patients with carbon monoxide intoxication: A population-based cohort study. Medicine 2015, 94, e869. Kenborg, L.; Rugbjerg, K.; Lee, P.-C.; Ravnskjær, L.; Christensen, J.; Ritz, B.; Lassen, C.F. Head injury and risk for Parkinson disease: Results from a Danish case-control study. Neurology 2015, 84, 1098–1103 Selvaraj, S.; Piramanayagam, S. Impact of gene mutation in the development of Parkinson’s disease. Genes Dis. 2019, 6, 120–128. Hauser, D.N.; Hastings, T.G. Mitochondrial dysfunction and oxidative stress in Parkinson’s disease and monogenic parkinsonism. Neurobiol. Dis. 2013, 51, 35–42. McCann, H.; Stevens, C.H.; Cartwright, H.; Halliday, G.M. alpha-Synucleinopathy phenotypes. Parkinsonism Relat. Disord. 2014, 20, S62–S67. Burré, J. The Synaptic Function of α-Synuclein. J. Parkinson’s Dis. 2015, 5, 699–713. Guardia-Laguarta, C.; Area-Gomez, E.; Schon, E.A.; Przedborski, S. Novel subcellular localization for α-synuclein: Possible functional consequences. Front. Neuroanat. 2015, 9, 17. Siddiqui, I.J.; Pervaiz, N.; Abbasi, A.A. The Parkinson Disease gene SNCA: Evolutionary and structural insights with pathological implication. Sci. Rep. 2016, 6, 24475. Wakabayashi, K.; Tanji, K.; Mori, F.; Takahashi, H. The Lewy body in Parkinson’s disease: Molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathol. Off. J. Jpn. Soc. Neuropathol. 2007, 27, 494–506 Gibson, G.E.; Park, L.C.; Sheu, K.F.; Blass, J.P.; Calingasan, N.Y. The alpha-ketoglutarate dehydrogenase complex in neurodegeneration. Neurochem. Int. 2000, 36, 97–112. Schapira, A.H.V.; Cooper, J.M.; Dexter, D.; Clark, J.B.; Jenner, P.; Marsden, C.D. Mitochondrial Complex I Deficiency in Parkinson’s Disease. J. Neurochem. 1990, 54, 823–827. McNaught, K.; Olanow, C. Proteolytic stress: A unifying concept for the etiopathogenesis of Parkinson’s disease. Ann. Neurol. 2003, 53, S73–S84. Ebrahimi-Fakhari, D.; Wahlster, L.; McLean, P.J. Molecular chaperones in Parkinson’s disease--present and future. J. Parkinson’s Dis. 2011, 1, 299–320. Murphy, K.E.; Gysbers, A.M.; Abbott, S.K.; Spiro, A.S.; Furuta, A.; Cooper, A.; Garner, B.; Kabuta, T.; Halliday, G.M. Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson’s disease. Mov. Disord. 2015, 30, 1639–1647. Riboldi, G.M.; Di Fonzo, A.B. GBA, Gaucher Disease, and Parkinson’s Disease: From Genetic to Clinic to New Therapeutic Approaches. Cells 2019, 8, 364. Berardelli, A.; Rothwell, J.C.; Thompson, P.D.; Hallett, M. Pathophysiology of bradykinesia in Parkinson’s disease. Brain 2001, 124, 2131–2146. Vingerhoets, F.J.; Schulzer, M.; Calne, D.B.; Snow, B.J. Which clinical sign of Parkinson’s disease best reflects the nigrostriatal lesion? Ann. Neurol. 1997, 41, 58–64. Jankovic, J.; Schwartz, K.S.; Ondo, W. Re-emergent tremor of Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 1999, 67, 646–650 Shahed, J.; Jankovic, J. Exploring the relationship between essential tremor and Parkinson’s disease. Parkinsonism Relat. Disord. 2007, 13, 67–76 Riley, D.; Lang, A.E.; Blair, R.D.; Birnbaum, A.; Reid, B. Frozen shoulder and other shoulder disturbances in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 1989, 52, 63–66. Williams, D.R.; Watt, H.C.; Lees, A.J. Predictors of falls and fractures in bradykinetic rigid syndromes: A retrospective study. J. Neurol. Neurosurg. Psychiatry 2006, 77, 468–473. Shivitz, N.; Koop, M.M.; Fahimi, J.; Heit, G.; Bronte-Stewart, H.M. Bilateral subthalamic nucleus deep brain stimulation improves certain aspects of postural control in Parkinson’s disease, whereas medication does not. Mov. Disord. Off. J. Mov. Disord. 2006, 21, 1088–1097. Carlsson, A.; Lindqvist, M.; Magnusson, T.O.R. 3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists. Nature 1957, 180, 1200. Goldenberg, M.M. Medical management of Parkinson’s disease. Pharm. Ther. 2008, 33, 590–606. Papavasiliou, P.S.; Cotzias, G.C.; Duby, S.E.; Steck, A.J.; Fehling, C.; Bell, M.A. Levodopa in Parkinsonism: Potentiation of central effects with a peripheral inhibitor. N. Engl. J. Med. 1972, 286, 8–14. Fox, S.H.; Lang, A.E. Levodopa-related motor complications—Phenomenology. Mov. Disord. 2008, 23, S509–S514 Schapira, A.; Olanow, C.W. Principles Of Treatment In Parkinson’s Disease; Elsevier Health Sciences: Amsterdam, The Netherlands, 2005. Jankovic, J.; Aguilar, L.G. Current approaches to the treatment of Parkinson’s disease. Neuropsychiatr. Dis. Treat. 2008, 4, 743–757. |